BioClinica and C.R. Bard Win 2012 Microsoft Life Sciences Innovation Award

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced that it is, together with C.R. Bard, a 2012 winner of Microsoft Corporation’s prestigious Life Sciences Innovation Award. The awards, announced at the Drug Information Association’s (DIA) 48th Annual Meeting in Philadelphia, honor companies that use Microsoft solutions to realize business and information technology benefits. BioClinica was recognized for revolutionizing medicine development by helping its clients bring therapeutic breakthroughs to the market faster, fight serious ailments, improve healthcare, and enhance people's quality of life.

“Now more than ever, the life sciences industry is faced with many challenges including cutting costs and bringing new drugs and therapies to market faster”

“Now more than ever, the life sciences industry is faced with many challenges including cutting costs and bringing new drugs and therapies to market faster,” said Andrea McGonigle, national managing director, Life Sciences, Microsoft Corporation. “We are impressed with how the winners demonstrate sustainable impacts through technology, and are proud that Microsoft’s software plays an important role in enabling these achievements in life sciences.”

BioClinica was recognized for the "Monitor Visit Report" capability of its OnPoint Clinical Trial Management System, developed for C.R. Bard, which makes it easier for clinical site monitors to enter essential study information. By synchronizing local Word documents through SharePoint, the data becomes a connected list which is then transferred and updated within OnPoint CTMS. Site monitors can complete forms anywhere, always benefiting from maximum ‘local quality’ intelligence, and synchronize the data with the web-based CTMS system whenever internet connectivity is present resulting in time savings of thousands of hours and dramatically reducing trial costs.

BioClinica and C.R. Bard were chosen for this award from a collection of life sciences corporations in the pharmaceutical, biotechnology and medical device industries that are creatively applying technology to develop therapeutic innovations. Winners were selected by a panel of industry experts. See more on the Microsoft website at http://www.microsoft.com/lifesciences and on the Microsoft in Health blog at http://blogs.msdn.com/b/microsoft_in_health/.

“We are honored to have C.R. Bard and BioClinica receive this award in recognition of our partnership to bring new innovations to market. The power of being able to run a clinical trial from one's Microsoft Outlook client is extremely powerful as visit reports, open action items, clinical documents and monitoring visits are available everywhere, anytime. The moment you connect to a network everything is instantly updated, something which no other CTMS or clinical suite of products has the power to do,” said Peter Benton, President, eClinical Division of BioClinica.

BioClinica is also demonstrating Express EDC and OnPoint CTMS Metro apps on slate computers running beta versions of Windows 8 at the Drug Information Association conference, June 24 – 28, 2012 at the Pennsylvania Convention Center in Philadelphia. To see the apps in action, or to learn more about BioClinica’s eClinical solutions and Imaging Core Lab services, visit the BioClinica booth, number 2707.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.